Who Paid My Doc
Xeloda
Drug BioOncology
NDC 0004-1101-50
General payments
$178
Research payments
$9,647,833
Through program year 2025, $178 in general payments and $9,647,833 in research payments were reported against Xeloda (BioOncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
10 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $426,992 | 51 |
| 2024 | Research | $185,380 | 50 |
| 2023 | Research | $693,185 | 74 |
| 2022 | General | $31 | 3 |
| 2022 | Research | $4,565,584 | 475 |
| 2021 | Research | $2,254,454 | 288 |
| 2020 | General | $113 | 1 |
| 2020 | Research | $510,174 | 67 |
| 2019 | General | $34 | 1 |
| 2019 | Research | $1,012,063 | 67 |
Breakdown
Each share is of general payments naming this product in 2022.
Each share is of general payments naming this product to practitioners with a specialty in 2022. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2022 where a state was reported.
Records
5 general · 1,072 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.